GHRP-2: FDA Status and Evidence
A growth hormone releasing peptide on FDA's Category 2 list for 503B compounding. It is not FDA-approved, and its human evidence is limited to short-term physiology studies.
Medically reviewed by Charles Kamen, MD, board-certified neurologist · ·
What the research shows
GHRP-2 has been studied mainly as a way to stimulate and measure growth hormone release in research settings. There are no long-term outcome trials supporting its use for anti-aging, body composition or recovery.
It is on the World Anti-Doping Agency prohibited list.
Frequently Asked Questions
Is GHRP-2 FDA-approved?
No. GHRP-2 is not an FDA-approved drug in the U.S.
Can a pharmacy compound GHRP-2?
FDA lists GHRP-2 in Category 2 for 503B outsourcing facilities, a list of substances that may present significant safety risks. Check the live FDA lists, which change.
What does the research show?
Short-term physiology studies show it raises growth hormone. There is no outcome evidence for wellness or longevity use.
Selected Research
Peer-reviewed sources on GHRP-2. Research does not constitute a treatment recommendation; appropriateness is determined only after a medical evaluation.
Related Growth hormone support
GHRP-6
A growth-hormone-releasing peptide studied for recovery and appetite - physician-supervised in Las Vegas.
IGF-1 LR3
An insulin-like growth factor peptide studied for recovery and growth - physician-supervised in Las Vegas.
Sermorelin
A growth-hormone-releasing peptide studied for energy, body composition, and recovery - physician-supervised in Las Vegas.
CJC-1295 & Ipamorelin
A commonly paired GHRH/GHRP peptide combination studied for recovery and body composition - physician-supervised in Las Vegas.